What Chemi-Tech does

Chemi-Tech, formally Chongqing Nansong Chemi-Tech Pharma Co., Ltd. (重庆南松凯博生物制药有限公司), is a Chongqing-based specialty chemical manufacturer established in 1992 (operating subsidiary) that produces pharmaceutical intermediates, cosmetic ingredients, pharmaceutical excipients, and other fine chemicals. The company operates as both a Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO), serving pharmaceutical manufacturers and cosmetics consumer enterprises. Its core technical competencies are catalytic hydrogenation, amination, and high-temperature high-vacuum distillation, each backed by over 30 years of process expertise, supported by a multi-functional pilot plant for product scale-up and process validation.

The company's product portfolio is organized into four categories: pharmaceutical intermediates (including intermediates for Chloroquine, Hydroxychloroquine sulfate, Mifepristone, and Nebivolol), cosmetic ingredients (UV absorbers, surfactants, and lubricants), high-end pharmaceutical excipients (Croscarmellose Sodium, Tert-butyl alcohol), and other fine chemicals (Diamylamine, Piperonyl butoxide). Production is conducted at a 66,055 sqm facility in Banan District, Chongqing, with reactor capacity exceeding 300 cubic meters and an integrated 500 m³/day wastewater treatment system. Chemi-Tech is a wholly-owned subsidiary of Chongqing Nansong Chemi-Tech Co., Ltd., which is itself a holding subsidiary of A-share listed Guangxi Hechi Chemical Co., Ltd. (Shenzhen Stock Exchange, SZ.000953).

Chemi-Tech generates revenue through direct B2B sales of its chemical products and through CMO/CDMO service contracts spanning project initiation, R&D, and commercial production. It holds independent import-export rights and exports 60% of its output to customers across Europe, the Americas, India, and China, with the remaining 40% serving domestic markets. The company is certified to ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 standards, recognized as a Chinese High-Tech Enterprise and Specialized and Sophisticated SME, and operates with a headcount of 11-50 employees.

Name

Chemi-Tech

Legal name

Chongqing Nansong Chemi-Tech Pharma Co., Ltd.

Website

https://chemi-tech.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

Chemi-Tech is a Chongqing-based specialty chemical manufacturer and CMO/CDMO producing pharmaceutical intermediates, cosmetic ingredients, and excipients. It serves global pharmaceutical and cosmetics enterprises via catalytic hydrogenation, amination, and high-vacuum distillation capabilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Chemical Manufacturing (325)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical intermediates
• Fine chemicals manufacturing
• Contract manufacturing services
• Cosmetic ingredients supply
• Active pharmaceutical ingredients

Headquarters

HQ city

Banan

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Infrastructure, Operations, Personnel

Revenue model

1. Product Sales: Sale of pharmaceutical intermediates, cosmetic ingredients, pharmaceutical excipients, and fine chemicals. The company manufactures and sells APIs and intermediates used in drugs like Chloroquine, Hydroxychloroquine sulfate, Mifepristone, Nebivolol, and others.
2. CMO and CDMO Services: Contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services for pharmaceutical and cosmetics enterprises, providing products spanning project initiation, R&D, and production.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Chemi-Tech manufactures and supplies pharmaceutical intermediates, cosmetic ingredients, pharmaceutical excipients, and other fine chemicals used in antimalarial, cardiovascular, CNS, and other drugs (including Chloroquine, Hydroxychloroquine sulfate, Mifepristone, and Nebivolol). The company also provides CMO and CDMO services spanning project initiation, R&D, and commercial production for pharmaceutical and cosmetics enterprises worldwide. Its specialized production capabilities include catalytic hydrogenation, amination, and high-temperature and high-vacuum distillation, supported by a multi-functional pilot plant and over 300 cubic meters of reactor capacity.

Product overview

Chongqing Nansong Chemi-Tech Pharma Co., Ltd. is a high-tech enterprise that integrates chemical active pharmaceutical ingredients (APIs) and pharmaceutical intermediates production with research and development. The company operates as both a Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO), providing services to pharmaceutical and cosmetics enterprises. The product portfolio consists of four main categories: Pharmaceutical Intermediates (31 products including Novaldiamine, Hydroxynovaldiamine, and various compounds for drugs like Chloroquine and Mifepristone), Cosmetic Ingredients (including UV absorbers, surfactants, and lubricants such as Neopentyl glycol diheptanoate), Pharmaceutical Excipients (including Croscarmellose Sodium and Tert-butyl alcohol), and Other Fine Chemicals (including Diamylamine and Piperonyl butoxide). The company specializes in hydrogenation, amination, and high-temperature and high-vacuum distillation processes.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Intermediates Chemical compounds used as intermediate steps in the synthesis of active pharmaceutical ingredients (APIs), including intermediates for drugs such as Chloroquine, Hydroxychloroquine sulfate, Quinacrine, Mifepristone, and Nebivolol. Sold to pharmaceutical manufacturers.
• Cosmetic Ingredients Raw materials for cosmetics and personal care products, including UV absorbers (Diethylamino hydroxybenzoyl hexyl benzoate, Bemotrizinol, 2-Ethylhexyl p-methoxycinnamate), surfactants (N-Stearoyl-L-glutamic acid disodium salt), and lubricants (Neopentyl glycol diheptanoate). Sold to cosmetics and consumer beauty enterprises.
• Pharmaceutical Excipients High-end pharmaceutical excipients including Croscarmellose Sodium (disintegrant) and Tert-butyl alcohol (freeze-drying protective agent). Sold to pharmaceutical manufacturers.
• Other Fine Chemicals Other fine chemical products including Diamylamine (CAS: 2050-92-2) for fine chemicals and Piperonyl butoxide (CAS: 51-03-6) as insecticide synergist. Sold to industrial and chemical buyers.
• CMO Services (Contract Manufacturing Organization) Contract manufacturing services for pharmaceutical and cosmetics enterprises, providing production capabilities for APIs and intermediates using specialized reactions (hydrogenation, amination, high-temperature and high-vacuum distillation).
• CDMO Services (Contract Development and Manufacturing Organization) Contract development and manufacturing organization services spanning project initiation, research and development, and commercial production for pharmaceutical manufacturers worldwide. Includes use of multi-functional pilot plant for product scale-up, process validation and optimization, and equipment feasibility testing.

Quantifiable outcome

• 60% of products exported overseas to Europe, Americas, India, and China

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Chongqing Nansong Chemi-Tech Co., Ltd. (Parent Company)coreOthersChongqing Nansong Chemi-Tech Pharma Co., Ltd. is a wholly-owned subsidiary of Chongqing Nansong Chemi-Tech Co., Ltd., which was founded in 1992. This is the parent-subsidiary corporate relationship within the same enterprise group.
• Guangxi Hechi Chemical Co., Ltd. (SZ.000953)coreOthersGuangxi Hechi Chemical Co., Ltd. (Shenzhen Stock Exchange, stock code SZ.000953) is an A-share listed company and the recognized holding subsidiary of Chongqing Nansong Chemi-Tech Co., Ltd. This represents the listed parent company relationship.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Laurus Labs: India-based API and CDMO manufacturer with global export reach into Europe and North America. Comparable in offering generic APIs/intermediates with specialized synthesis capabilities and a B2B contract manufacturing focus.
• Hikal: India-based fine chemicals and API manufacturer serving global pharma and agrochemical customers. Comparable in offering custom synthesis, intermediates, and APIs with similar export-driven B2B model and specialty chemistry capabilities.
• Zhejiang Huahai Pharmaceutical: China-based API manufacturer specializing in cardiovascular, CNS, and antimalarial active ingredients with significant international export presence. Comparable in product mix (chloroquine-class antimalarials, cardiovascular APIs) and export-led business model.
• Recipharm: European CDMO offering API and finished-dose contract manufacturing services to pharma customers globally. Comparable in integrated CMO/CDMO model with a focus on small-molecule chemistry and complex synthesis.
• Cambrex (Permira): US/Europe-based small-molecule CDMO specializing in API and intermediate manufacturing with a similar CMO/CDMO service model. Directly comparable in technology stack and customer mix, though based in Western markets with higher cost structure.
• Asymchem Laboratories: China-based CDMO specializing in small-molecule API and intermediate manufacturing with a similar integrated CMO/CDMO model serving global pharma customers. Directly comparable in technology stack (complex organic synthesis, hydrogenation) and customer mix (regulated international pharma buyers).
• Divi's Laboratories: India-based API and intermediate manufacturer with significant export exposure to regulated markets, serving both generic and innovator pharma customers. Highly comparable in product mix (complex intermediates and APIs) and export-led business model targeting Europe and the Americas.
• Apeloa Pharma: China-based API and intermediate manufacturer with both CMO/CDMO services and proprietary generic API products. Comparable in scale, geographic positioning, and dual business model serving domestic and international pharma customers.

Broad incumbents

• WuXi STA (WuXi AppTec): Largest China-based small-molecule CDMO offering drug substance and drug product services across a much broader portfolio. Competes with Chemi-Tech for Western pharma outsourcing programs but operates at significantly greater scale and capability breadth.
• Aurobindo Pharma: India-based vertically integrated generic manufacturer with large-scale API manufacturing and finished-dose capabilities. Comparable in producing APIs for antimalarials, cardiovascular, and CNS therapeutic areas, though much larger in scale and scope.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemi-Tech